Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit vascular smooth muscle cell proliferation via differential effects on the cell cycle

被引:38
作者
Brooks, G
Yu, XM
Wang, YQ
Crabbe, MJC
Shattock, MJ
Harper, JV
机构
[1] Univ Reading, Cardiovasc Res Grp, Sch Anim & Microbial Sci, Div Cell & Mol Biol, Reading RG6 6AJ, Berks, England
[2] Taishan Med Coll, Affiliated Hosp, Endocrinol Sect, Dept Med, Tai An, Shandong, Peoples R China
[3] Hunan Normal Univ, Coll Life Sci, Changsha 410081, Hunan, Peoples R China
[4] St Thomas Hosp, Univ London Kings Coll, Rayne Inst, Ctr Cardiovasc Biol & Med, London SE1 7EH, England
关键词
D O I
10.1211/002235702775
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Abnormal vascular smooth muscle cell (VSMC) proliferation plays an important role in the pathogenesis of both atherosclerosis and restenosis. Recent studies suggest that high-dose salicylates, in addition to inhibiting cyclooxygenase activity, exert an antiproliferative effect on VSMC growth both in-vitro and in-vivo. However, whether all non-steroidal anti-inflammatory drugs (NSAIDs) exert similar anti proliferative effects on VSMCs, and do so via a common mechanism of action, remains to be shown. In this study, we demonstrate that the NSAIDs aspirin, sodium salicylate, diclofenac, ibuprofen, indometacin and sulindac induce a dose-dependent inhibition of proliferation in rat A10 VSMCs in the absence of significant cytotoxicity. Flow cytometric analyses showed that exposure of A10 cells to diclofenac, indometacin, ibuprofen and sulindac, in the presence of the mitotic inhibitor, nocodazole, led to a significant G0/G1 arrest. In contrast, the salicylates failed to induce a significant G1 arrest since flow cytometry profiles were not significantly different from control cells. Cyclin A levels were elevated, and hyperphosphorylated p107 was present at significant levels, in salicylate-treated A10 cells, consistent with a post-G1/S block, whereas cyclin A levels were low, and hypophosphorylated p107 was the dominant form, in cells treated with other NSAIDs consistent with a G1 arrest. The ubiquitously expressed cyclin-dependent kinase (CDK) inhibitors, p21 and p27, were increased in all NSAID-treated cells. Our results suggest that diclofenac, indometacin, ibuprofen and sulindac inhibit VSMC proliferation by arresting the cell cycle in the G1 phase, whereas the growth inhibitory effect of salicylates probably affects the late S and/or G2/M phases. Irrespective of mechanism, our results suggest that NSAIDs might be of benefit in the treatment of certain vasculoproliferative disorders.
引用
收藏
页码:519 / 526
页数:8
相关论文
共 29 条
  • [1] GROWTH-INHIBITION OF RAT GLIOMA-CELLS IN-VITRO AND IN-VIVO BY ASPIRIN
    AAS, AT
    TONNESSEN, TI
    BRUN, A
    SALFORD, LG
    [J]. JOURNAL OF NEURO-ONCOLOGY, 1995, 24 (02) : 171 - 180
  • [2] BLAKYTNY R, 1992, EXP EYE RES, V54, P509
  • [3] BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
  • [4] Arresting developments in the cardiac myocyte cell cycle: Role of cyclin-dependent kinase inhibitors
    Brooks, G
    Poolman, RA
    Li, JM
    [J]. CARDIOVASCULAR RESEARCH, 1998, 39 (02) : 301 - 311
  • [5] BROOKS G, 1993, J BIOL CHEM, V268, P23868
  • [6] Expression and activities of cyclins and cyclin dependent kinases in developing rat ventricular myocytes
    Brooks, G
    Poolman, RA
    McGill, CJ
    Li, JM
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1997, 29 (08) : 2261 - 2271
  • [7] The cell cycle and drug discovery: the promise and the hope
    Brooks, G
    La Thangue, NB
    [J]. DRUG DISCOVERY TODAY, 1999, 4 (10) : 455 - 464
  • [8] p107 and p130: Versatile proteins with interesting pockets
    Classon, M
    Dyson, N
    [J]. EXPERIMENTAL CELL RESEARCH, 2001, 264 (01) : 135 - 147
  • [9] TREATMENT OF COLONIC AND RECTAL ADENOMAS WITH SULINDAC IN FAMILIAL ADENOMATOUS POLYPOSIS
    GIARDIELLO, FM
    HAMILTON, SR
    KRUSH, AJ
    PIANTADOSI, S
    HYLIND, LM
    CELANO, P
    BOOKER, SV
    ROBINSON, CR
    OFFERHAUS, GJA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (18) : 1313 - 1316
  • [10] Herfindal ET, 1996, TXB THERAPEUTICS DRU